ClinicalTrials.gg

Program

elranatamab

Also written as “Elranatamab”, “Elranatamab (PF-06863135)” and “Elranatamab + Nirogacestat”.

Its studies are mostly in Multiple Myeloma, led by 3 companies.

Furthest: phase 4, since Sep 5, 202315 company-led studies, 9 open or runningNext primary completion: May 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer137 open or runningphase 4since Sep 5, 2023Aug 16, 2017Aug 4, 2027phase 3 · NCT05317416
Bristol-Myers Squibb11 open or runningphase 2since May 16, 2025May 16, 2025May 31, 2027phase 2 · NCT06988488
Hoffmann-La Roche11 open or runningphase 1since Jun 22, 2023Jun 22, 2023Jul 31, 2027phase 1 · NCT05927571

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Aug 16, 2017.

  1. Nov 6, 2020Phase 2 study in Multiple MyelomaPfizer · NCT04649359 · 187 enrolled · United States, Australia, Belgium and more
  2. Mar 1, 2021Phase 1 study in RecurrencePfizer · NCT04798586 · 4 enrolled · Japan
  3. Aug 3, 2021Phase 2 study in Multiple MyelomaPfizer · NCT05014412 · 86 enrolled · United States, Japan, Taiwan and more
  4. Aug 11, 2021Phase 3 study in Multiple MyelomaPfizer · NCT05020236 · 893 planned · United States, Argentina, Australia and more
  5. Oct 8, 2021Phase 2 study in Multiple MyelomaPfizer · NCT05090566 · 46 enrolled · United States, Canada
  6. Jan 5, 2022Phase 2 study in Neoplasms, Plasma CellPfizer · NCT05228470 · 39 enrolled · China
  7. Mar 18, 2022Phase 3 study in Multiple MyelomaPfizer · NCT05317416 · 854 enrolled · United States, Australia, Austria and more
  8. Oct 26, 2022Phase 3 study in Multiple MyelomaPfizer · NCT05623020 · 1,060 planned · United States, Argentina, Australia and more
  9. Jun 22, 2023Hoffmann-La Roche's first study: phase 1 study in RecurrenceNew to Hoffmann-La RocheHoffmann-La Roche · NCT05927571 · 120 planned · Australia, Israel, South Korea
  10. Sep 5, 2023Phase 4 study in Multiple MyelomaPfizer · NCT06057402 · 80 planned · United States, Australia, Canada and more
  11. Nov 17, 2023Phase 3 study in Multiple MyelomaPfizer · NCT06152575 · 492 planned · United States, Argentina, Australia and more
  12. Jan 10, 2024Phase 1 study in Multiple MyelomaPfizer · NCT06215118 · 100 enrolled · United States, Australia, Canada
  13. May 16, 2025Bristol-Myers Squibb's first study: phase 2 study in Multiple MyelomaNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT06988488 · 62 planned · United States, Canada, China and more
  14. Oct 13, 2026Phase 4 study in Multiple MyelomaPfizer · NCT07881835 · 75 planned

Ahead

  1. May 31, 2027Primary completion: phase 2 study in Multiple MyelomaBristol-Myers Squibb · NCT06988488
  2. Jul 31, 2027Primary completion: phase 1 study in RecurrenceHoffmann-La Roche · NCT05927571
  3. Aug 4, 2027Primary completion: phase 3 study in Multiple MyelomaPfizer · NCT05317416
  4. Nov 16, 2027Primary completion: phase 1 study in Multiple MyelomaPfizer · NCT06215118

TargetBeta

“A bispecific monoclonal antibody against human CD3, a T-cell surface antigen, and human B-cell maturation antigen (BCMA; TNFRSF17), a tumor-associated antigen (TAA) expressed on plasma cells, ”NCIt, by rule
“T cell surface glycoprotein CD3 binding agent; Tumor necrosis factor receptor superfamily member 17 binding agent”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
linvoseltamabruleRegeneron Pharmaceuticalsphase 413
teclistamabruleJohnson & Johnsonphase 411
etentamigAbbViephase 311
ramantamigJohnson & Johnsonphase 37
Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934Sino Biopharmaceuticalphase 34
GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003ruleInnovent Biologicsphase 34
cizutamigruleUCBphase 25
vonsetamigruleRegeneron Pharmaceuticalsphase 23
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbViephase 22
LVV Expressing VSV Glycoprotein/Anti-CD3 scFv Containing Transgene Encoding for Anti-BCMA CAR KLN-1010rulekelonia-therapeutics-incphase 11

Studies

All 15 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07881835Multiple Myeloma4Not yet recruitingPfizerFeb 16, 202975
NCT06988488Multiple Myeloma · United States, Canada, China and more2RecruitingBristol-Myers SquibbMay 31, 202762
NCT06215118Multiple Myeloma · United States, Australia, Canada1Active, not recruitingPfizerNov 16, 2027100
NCT06152575Multiple Myeloma · United States, Argentina, Australia and more3RecruitingPfizerAug 26, 2026492
NCT06057402Multiple Myeloma · United States, Australia, Canada and more4RecruitingPfizerFeb 22, 203280
NCT05927571Recurrence · Australia, Israel, South Korea1RecruitingHoffmann-La RocheJul 31, 2027120
NCT05623020Multiple Myeloma · United States, Argentina, Australia and more3RecruitingPfizerOct 18, 20301,060
NCT05317416Multiple Myeloma · United States, Australia, Austria and more3Active, not recruitingPfizerAug 4, 2027854
NCT05228470Neoplasms, Plasma Cell · China2CompletedPfizerAug 6, 202339
NCT05090566Multiple Myeloma · United States, Canada2TerminatedPfizerFeb 13, 202546
NCT05020236Multiple Myeloma · United States, Argentina, Australia and more3RecruitingPfizerFeb 26, 2026893
NCT05014412Multiple Myeloma · United States, Japan, Taiwan and more2CompletedPfizerJun 15, 202386
NCT04798586Recurrence · Japan1CompletedPfizerMay 27, 20224
NCT04649359Multiple Myeloma · United States, Australia, Belgium and more2CompletedPfizerJun 17, 2022187
NCT03269136Multiple Myeloma · United States, Canada1CompletedPfizerJan 19, 2024101

How it is read

Names in the registry

  • “Elranatamab”, 12 entries
  • “Elranatamab (PF-06863135)”, 2 entries
  • “Elranatamab + Nirogacestat”, 1 entry
  • “Elranatamab + lenalidomide + dexamethasone”, 1 entry
  • “PF-06863135 monotherapy IV or SC”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.